Brexpiprazole alters monoaminergic systems following repeated administration: An in vivo electrophysiological study

International Journal of Neuropsychopharmacology

Volumn 19, Issue 3, 2015, Pages 1-12

  Oosterhof, Chris A ^a,b   Mansari, Mostafa El ^a   Bundgaard, Christoffer ^c   Blier, Pierre ^a,b  

^a Clinical Epidemiology Program   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c H LUNDBECK A S   (Denmark)

Author keywords

brexpiprazole; dopamine; norepinephrine; serotonin; single unit electrophysiological recordings

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BREXPIPRAZOLE; CHLORAL HYDRATE; DOPAMINE AUTORECEPTOR; NORADRENALIN; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE; NEUROTRANSMITTER RECEPTOR; PSYCHOTROPIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; FIRING RATE; HIPPOCAMPAL CA3 REGION; IN VIVO STUDY; LOCUS CERULEUS; MALE; MONOAMINERGIC SYSTEM; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; REPEATED DRUG DOSE; SEROTONINERGIC NERVE CELL; VENTRAL TEGMENTUM; ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; BRAIN; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME FACTOR; TISSUE CULTURE TECHNIQUE;

ACTION POTENTIALS; ANIMALS; BODY WEIGHT; BRAIN; DOPAMINE; MALE; NEURONS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PSYCHOTROPIC DRUGS; QUINOLONES; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTRANSMITTER; SEROTONIN; THIOPHENES; TIME FACTORS; TISSUE CULTURE TECHNIQUES;

EID: 84963959522     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv111     Document Type: Article

References (59)

1. Besson A, Haddjeri N, Blier P, de Montigny C (2000) Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 10:177-188.
2. Blier P, El Mansari M (2013) Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 368:20120536.
3. Blier P, Ramdine R, Galzin AM, Langer SZ (1989) Frequencydependence of serotonin autoreceptor but not alpha 2-adrenoceptor inhibition of [3H]-serotonin release in rat hypothalamic slices. Naunyn Schmiedebergs Arch Pharmacol 339:60-64.
4. Blier P, Szabo ST (2005) Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 66:30-40.
5. Blier P, Ward NM (2003) Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53:193-203.
6. Chaput Y, Blier P, de Montigny C (1986) In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci 6:2796-2801.
7. Chenu F, El Mansari M, Blier P (2013) Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 38:275-284.
8. Chernoloz O, El Mansari M, Blier P (2009) Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl) 206:335-344.
9. Chernoloz O, El Mansari M, Blier P (2012) Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Neuropsychopharmacology 37:1717-1728.
10. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619.
11. Curet O, de Montigny C (1988) Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus. I. Receptors mediating the effect of microiontophoretically applied norepinephrine. Brain Res 475:35-46.
12. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N (2009) Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 23:177-189.
13. De Montigny C, Aghajanian GK (1978) Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202:1303-1306.
14. De Montigny C, Wang RY, Reader TA, Aghajanian GK (1980) monoaminergic denervation of the rat hippocampus: microiontophoretic studies on pre-and postsynaptic supersensitivity to norepinephrine and serotonin. Brain Res 200:363-376.
15. Dong J, de Montigny C, Blier P (1998) Full agonistic properties of BAY x 3702 on presynaptic and postsynaptic 5-HT1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe. J Pharmacol Exp Ther 286:1239-1247.
16. Dremencov E, El Mansari M, Blier P (2007a) Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 61:671-678.
17. Dremencov E, El Mansari M, Blier P (2007b) Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 194:63-72.
18. Ghanbari R, El Mansari M, Blier P (2010) Sustained administration of trazodone enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain. J Pharmacol Exp Ther 335:197-206.
19. Ghanbari R, El Mansari M, Blier P (2011) Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology (Berl) 217:61-73.
20. Ghanbari R, El Mansari M, Shahid M, Blier P (2009) Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha 2-adrenergic, and D2 receptors in the rat brain. Eur Neuropsychopharmacol 19:177-187.
21. Ghanbari R, Mansari M El, Blier P (2012) Electrophysiological impact of trazodone on the dopamine and norepinephrine systems in the rat brain. Eur Neuropsychopharmacol 22:518-526.
22. Grace AA, Bunney BS (1984) The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890.
23. Haddjeri N, Blier P, de Montigny C (1998) Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18:10150-10156.
24. Haj-Dahmane S (2001) D2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro. Eur J Neurosci 14:125-134.
25. Hajos M, Allers KA, Jennings K, Sharp T, Charette G, Sik A, Kocsis B (2007) Neurochemical identification of stereotypic burstfiring neurons in the rat dorsal raphe nucleus using juxtacellular labelling methods. Eur J Neurosci 25:119-126.
26. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T (2004) Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side effect profile. J Psychopharmacol 18:375-383.
27. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapines antidepressant activity. Neuropsychopharmacology 33:2303-2312.
28. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 164:127-135.
29. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
30. Kuroki T, Nagao N, Nakahara T (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 172:199-212.
31. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci 93:9235-9240.
32. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbol TB, Bundgaard C, Arnt J, Kikuchi T (2014a) Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:605-614.
33. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mork A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbol TB, Kikuchi T (2014b) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589-604.
34. Mongeau R, Blier P, de Montigny C (1993) In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 347:266-272.
35. Oosterhof CA, El Mansari M, Blier P (2014) Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther 351:585-595.
36. Oosterhof CA, El Mansari M, Blier P (2015) Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: an in vivo electrophysiological characterization. Eur Neuropsychopharmacol 25:531-543.
37. Oosterhof NN, Oosterhof CA (2013) BurstiDAtor: a lightweight discharge analysis program for neural extracellular single unit recordings. https://github.com/nno/burstiDAtor. Retrieved 21 Oct 2014.
38. Piñeyro G, Blier P, Dennis T, de Montigny C (1994) Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 14:3036-3047.
39. Ramirez OA, Wang RY (1986) Locus coeruleus norepinephrine-containing neurons: effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine. Brain Res 362:165-170.
40. Ranck JB (1973) Studies on single neurons in dorsal hippocampal formation and septum in unrestrained rats. I. Behavioral correlates and firing repertoires. Exp Neurol 41:461-531.
41. Rao NP, Remington G (2013) Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials. Expert Opin Investig Drugs 22:881-894.
42. Rueter LE, De Montigny C, Blier P (1998) Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther 285:404-412.
43. Seager MA, Barth VN, Phebus LA, Rasmussen K (2005) Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl) 181:126-133.
44. Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219.
45. Shahid M, Walker GB, Zorn SH, Wong EHF (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65-73.
46. Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289-294.
47. Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A (2015) Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA psychiatry 72:316-324.
48. Stahl SM (2008) Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr 13:279-282.
49. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD (2007) Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 190:373-382.
50. Stip E, Tourjman V (2010) Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 32:S3-20.
51. Svensson TH, Bunney BS, Aghajanian GK (1975) Inhibition of both noradrenergic and serotonergic neurons in brain by the a-adrenergic agonist clonidine. Brain Res 92:291-306.
52. Szabo ST, Blier P (2001) Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 922:9-20.
53. Tarazi FI, Stahl SM (2012) Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 13:1911-1922.
54. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H (2015a) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 76(9):1224-1231.
55. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015b) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 76(9):1232-1240.
56. Vandermaelen CP, Aghajanian GK (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 289:109-119.
57. Vogelsang GD, Piercey MF (1985) The supersensitivity of dopaminergic neurons to apomorphine in rats following chronic haloperidol. Eur J Pharmacol 110:267-269.
58. Westerink BHC, De Boer P, De Vries JB, Kruse CG, Long SK (1998) Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 361:27-33.
59. Yoshimi N, Fujita Y, Ohgi Y, Futamura T, Kikuchi T, Hashimoto K (2014) Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav 124C:245-249.